MYC and autosomal dominant polycystic kidney disease: Conditional Taz deletion in Pkd1-null mice reduced cyst growth and improved renal function, highlighting the PKD1–TAZ–β-catenin–c-Myc axis as a key therapeutic target in ADPKD [9].